GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Alphamab Oncology 9966.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

6.34

+1.28%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥643.2m

FY2017FY2025

Net income

−CN¥129.4m

FY2017FY2025

Free cash flow

−CN¥179.0m

FY2017FY2025

Shareholders' equity

CN¥2.00bn

FY2017FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
RevenueCN¥643.2mCN¥640.1mCN¥218.8mCN¥166.8mCN¥170.3m—CN¥5.0m−CN¥735,000CN¥1.2m
Research and developmentCN¥576.5mCN¥404.2mCN¥407.5mCN¥468.2mCN¥561.3mCN¥331.2mCN¥166.7mCN¥65.6mCN¥53.2m
Operating income−CN¥174.1mCN¥101.0m−CN¥305.6m−CN¥432.4m−CN¥465.5m−CN¥409.4m−CN¥829.1m−CN¥92.2m−CN¥64.8m
Net income−CN¥129.4mCN¥166.3m−CN¥210.6m−CN¥325.7m−CN¥480.9m−CN¥427.8m−CN¥836.3m−CN¥149.8m−CN¥33.1m
Diluted earnings per share-0.130.17-0.22-0.35-0.51-0.46-0.93-0.17-0.04

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Total assetsCN¥2.45bnCN¥2.61bnCN¥2.49bnCN¥2.47bnCN¥3.15bnCN¥2.64bnCN¥2.85bnCN¥826.9mCN¥46.6m
Cash and short-term investmentsCN¥1.57bnCN¥1.83bnCN¥1.64bnCN¥1.57bnCN¥2.32bnCN¥2.06bnCN¥2.38bnCN¥633.7mCN¥657,000
Total liabilitiesCN¥450.5mCN¥478.0mCN¥542.2mCN¥652.9mCN¥973.5mCN¥366.4mCN¥428.7mCN¥1.09bnCN¥20.3m
DebtCN¥141.0mCN¥186.0mCN¥257.1mCN¥345.4mCN¥637.3mCN¥222.8mCN¥253.2mCN¥1.01bn—
Shareholders' equityCN¥2.00bnCN¥2.14bnCN¥1.95bnCN¥1.82bnCN¥2.18bnCN¥2.27bnCN¥2.43bn−CN¥267.0mCN¥13.4m
Shares outstanding961m1,006m963m937m936m935m897m897m897m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash from operations−CN¥142.1mCN¥212.3m−CN¥236.5m−CN¥350.2m−CN¥373.9m−CN¥347.2m−CN¥225.5m−CN¥93.9m−CN¥65.2m
Capital spending−CN¥36.8m−CN¥21.8m−CN¥42.2m−CN¥151.2m−CN¥184.4m−CN¥90.8m−CN¥171.4m−CN¥73.1m−CN¥8.3m
Free cash flow−CN¥179.0mCN¥190.6m−CN¥278.7m−CN¥501.4m−CN¥558.2m−CN¥438.0m−CN¥396.9m−CN¥167.0m−CN¥73.5m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
RevenueCN¥316.6mCN¥283.0mCN¥372.5mCN¥466.5mCN¥173.6mCN¥82.3mCN¥159.1mCN¥132.1m
Operating income−CN¥51.6m−CN¥176.5mCN¥490,928CN¥187.5m−CN¥86.5m−CN¥198.7m−CN¥145.3m−CN¥245.6m
Net income−CN¥47.2m−CN¥155.4mCN¥25.2mCN¥211.2m−CN¥44.9m−CN¥170.7m−CN¥46.5m−CN¥208.0m
Diluted earnings per share-0.05-0.160.030.21-0.04-0.18-0.05-0.22
Cash from operations—−CN¥119.0m−CN¥2.0mCN¥258.0m−CN¥45.0m−CN¥150.0m−CN¥85.0m−CN¥179.0m
Capital spending—−CN¥11.0m−CN¥25.0m−CN¥16.0m−CN¥4.0m−CN¥16.0m−CN¥25.0m−CN¥75.0m
Free cash flow—−CN¥130.0m−CN¥27.0mCN¥242.0m−CN¥49.0m−CN¥166.0m−CN¥110.0m−CN¥254.0m
Total assetsCN¥2.52bnCN¥2.45bnCN¥2.75bnCN¥2.24bnCN¥2.14bnCN¥2.14bnCN¥2.72bnCN¥2.12bn
Cash and short-term investmentsCN¥1.67bnCN¥1.57bnCN¥1.92bnCN¥1.57bnCN¥1.46bnCN¥1.41bnCN¥1.84bnCN¥1.35bn
DebtCN¥245.6mCN¥141.0mCN¥318.9mCN¥186.0mCN¥326.6mCN¥257.1mCN¥330.7mCN¥345.4m
Shareholders' equityCN¥1.95bnCN¥2.00bnCN¥2.16bnCN¥1.83bnCN¥1.63bnCN¥1.67bnCN¥2.15bnCN¥1.56bn

Financial ratios

Data as of 9 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Operating margin-27.1%15.8%-90.7%-259.1%-273.4%—-5596.9%—
Net margin-20.1%26.0%-96.3%-195.2%-282.4%—-16753.7%—
Return on equity-6.5%9.1%-12.6%-20.9%-22.1%-18.8%——
Return on assets-5.3%7.4%-9.9%-15.4%-15.2%-16.2%——
Free cash flow yield-1.3%3.2%-2.4%-2.5%-2.4%-3.7%——
Revenue growth-13.8%192.6%31.1%14.3%——-779.2%-160.1%
Earnings growth-166.7%-179.0%-35.3%-21.0%-3.6%-48.9%——
Current ratio5.67x6.74x5.84x3.88x3.32x6.67x——
Debt to equity0.07x0.10x0.15x0.22x0.33x0.09x——
Equity ratio81.6%81.7%78.2%73.6%69.1%86.1%——
Interest coverage-20.58x10.18x-16.29x-30.44x-30.29x-34.62x——
R&D as a share of sales89.6%63.1%186.3%280.6%329.7%—3338.4%—
Buybacks as a share of market value4.4%-4.5%-2.7%-0.1%-0.1%-4.2%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue56.8%——
Operating income-26.2%-15.7%—
Net income-26.5%-21.3%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings-63.118.3-14.5-14.9-12.7-17.2-7.2
Price to sales12.74.814.029.035.8——

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.